to classify tumor microenvironments based on PD-L1 expression in tumor cells and tumor-infiltrating lymphocytes (TIL), RT may harbor a type I microenvironment (PDL1+, TIL+), reflecting an adaptive immune resistance environment, which can be the target of checkpoint inhibitors (48, 49). The gene discussed is CD274; the disease is neoplasm.